You just read:

Merrimack Announces Top-Line Results from Randomized Phase 2 Trial of MM-141 in Front-Line Metastatic Pancreatic Cancer

News provided by

Merrimack Pharmaceuticals, Inc.

Jun 25, 2018, 07:20 ET